Table 2.

CYP4A11 genotype and BP during follow-up^a

Parameter	Genotype
	3 Mo				36 Mo
	TT(n = 345)	CT(n = 322)	CC(n = 65)	P	TT(n = 314)	CT(n = 292)	CC(n = 57)	P
Usual BP
medications, n
men	1.7 ± 1.3b	2.1 ± 1.5	1.8 ± 1.2	0.18	2.1 ± 1.5b	2.3 ± 1.7b	2.0 ± 1.2b	0.46
women	1.5 ± 1.3	1.3 ± 1.1b,c	1.8 ± 1.5	0.32	2.0 ± 1.5	2.0 ± 1.5b	2.4 ± 1.7	0.72
all	1.6 ± 1.3b	1.8 ± 1.4b	1.8 ± 1.3	0.48	2.1 ± 1.5b	2.2 ± 1.6b	2.1 ± 1.4	0.74
SBP (mmHg)
men	139.1 ± 16.5b	143.4 ± 16.1b	146.3 ± 12.0b	0.07	140.2 ± 13.7b	142.3 ± 17.1b	143.3 ± 9.0	0.58
women	139.4 ± 17.7b	145.7 ± 19.0	145.3 ± 14.7b	0.12	141.7 ± 15.9b	143.9 ± 20.6b	135.2 ± 12.5	0.36
all	139.3 ± 17.0b	144.3 ± 17.3b,d	145.9 ± 12.8b,d	0.01	140.9 ± 14.7b	142.9 ± 18.5b	140.5 ± 10.9	0.54
DBP (mmHg)
men	87.7 ± 9.8b	89.4 ± 10.9b	88.7 ± 11.5b	0.53	86.8 ± 10.5b	87.2 ± 10.5b	87.1 ± 9.5	0.97
women	87.3 ± 11.2b	84.8 ± 11.0†	90.4 ± 10.8b	0.21	84.8 ± 9.3b	82.1 ± 11.6c	87.2 ± 8.8b	0.23
all	87.5 ± 10.4b	87.7 ± 11.2b	89.3 ± 11.1b	0.66	85.9 ± 10.0b	85.2 ± 11.2b	87.1 ± 9.1	0.66
Lower BP
medications, n
men	2.5 ± 1.4	2.3 ± 1.1	2.2 ± 1.3	0.55	2.9 ± 1.5	3.1 ± 1.5	2.9 ± 1.2	0.57
women	1.7 ± 1.3c	1.8 ± 1.3c	1.5 ± 0.9	0.71	2.4 ± 1.6	2.7 ± 1.5	2.0 ± 1.1	0.31
all	2.2 ± 1.4	2.1 ± 1.2	1.9 ± 1.2	0.52	2.7 ± 1.5	2.9 ± 1.5	2.6 ± 1.2	0.36
SBP (mmHg)
men	128.2 ± 17.2	126.8 ± 19.9	131.7 ± 20.2	0.55	124.6 ± 17.0	123.3 ± 17.0	139.1 ± 24.0d,e	0.004
women	132.2 ± 23.6	138.9 ± 24.2c	125.6 ± 15.2	0.10	126.4 ± 15.2	135.5 ± 22.8c,d	124.1 ± 19.3	0.03
all	129.6 ± 19.7	132.0 ± 22.6	129.5 ± 18.5	0.52	125.2 ± 16.3	128.5 ± 20.5	133.5 ± 23.2	0.08
DBP (mmHg)
men	80.2 ± 12.7	80.1 ± 12.9	80.0 ± 14.9	1.00	76.8 ± 10.6	75.9 ± 12.2	83.8 ± 16.4e	0.048
women	81.3 ± 14.0	82.8 ± 14.2	78.9 ± 9.2	0.61	76.4 ± 10.4	78.6 ± 11.5	77.8 ± 9.8	0.57
all	80.5 ± 13.1	81.3 ± 13.5	79.6 ± 12.9	0.76	76.7 ± 10.5	77.1 ± 11.9	81.6 ± 14.4	0.13

^aData are means ± SD.

^bP < 0.05 versus lower BP group.

^cP < 0.05 versus men.

^dP < 0.05 versus 8590TT.

^eP < 0.05 versus 8590CT.